Capio Biosciences
Biotechnology ResearchWisconsin, United States2-10 Employees
Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information to improve patient outcomes. Founded in 2015 by cofounders Seungpyo Hong PhD (UW, Madison WI) and Andrew Wang MD (UNC, Chapel Hill NC), Capio Biosciences is a biotech start-up focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. At Capio Biosciences we are currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.
1-888-653-2347 
support@leadiq.com 
